Bremelanotide is the active compound in both the FDA-approved product Vyleesi and the compounded PT-141 formulations available at Regen Doctors. This article provides an educational overview of bremelanotide’s mechanism, its FDA-approved indication, and the important distinctions between the FDA-approved product and compounded versions.
Bremelanotide is a melanocortin receptor agonist, specifically activating MC3R and MC4R receptors. These receptors are part of central nervous system pathways that research has associated with sexual arousal and motivation. This mechanism is different from PDE5 inhibitors (such as sildenafil or tadalafil), which work peripherally by relaxing smooth muscle in blood vessels. Bremelanotide does not work by affecting blood flow in the same way. Understanding this mechanistic difference can help patients and providers assess whether bremelanotide is a clinically appropriate option to explore.
The FDA approved bremelanotide injection 1.75mg/0.3mL (brand name Vyleesi) in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This approval was based on clinical trials involving specific patient populations with this specific diagnosis. The FDA-approved indication does not extend to all patients, all genders, or all sexual function concerns. Patients should discuss whether they fall within the studied population with their provider.
Regen Doctors offers compounded bremelanotide (PT-141) in nasal spray and injectable formats. These compounded formulations are not FDA-approved for safety, effectiveness, or quality. They are not the same as Vyleesi, even though they contain the same active ingredient. Compounded medications are prepared by licensed pharmacies and are not subject to the same FDA evaluation process as finished drug products.
Bremelanotide has a documented safety profile that patients must review with a provider before starting. Known side effects include nausea, flushing, and headache. Bremelanotide is not recommended for patients with certain cardiovascular conditions or uncontrolled hypertension. A full medical history review is conducted during the required provider consultation. No patient receives a prescription without a licensed provider first evaluating their health profile. No specific outcome is guaranteed.
*Educational Content Notice: This article is for informational purposes only and does not constitute medical advice. Compounded PT-141 is not FDA-approved. The FDA-approved bremelanotide product is Vyleesi. A valid prescription requires a licensed provider consultation. Individual responses vary and no specific outcome is guaranteed.
*Important Disclosures: Compounded PT-141 is not FDA-approved. The FDA-approved bremelanotide product is Vyleesi (bremelanotide injection, 1.75mg/0.3mL), indicated for acquired HSDD in premenopausal women. A valid prescription is required following a licensed provider consultation. Individual responses vary and no specific outcome is guaranteed. This content does not constitute medical advice. Not available internationally or in all states.
